Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021062089 - XANTHINE CB1 INHIBITORS

Publication Number WO/2021/062089
Publication Date 01.04.2021
International Application No. PCT/US2020/052627
International Filing Date 25.09.2020
IPC
A61K 31/375 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
365Lactones
375Ascorbic acid, i.e. vitamin C; Salts thereof
A61K 33/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
A61K 33/04 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
04Sulfur, selenium or tellurium; Compounds thereof
Applicants
  • GOLDFINCH BIO, INC. [US]/[US]
Inventors
  • YU, Maolin
  • WILLIAMS, Brett D.
  • LEDEBOER, Mark W.
  • HARMANGE, Jean-Christophe P.
  • CARRA, Sydney E.
Agents
  • GORDON, Dana M.
Priority Data
62/905,63825.09.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) XANTHINE CB1 INHIBITORS
(FR) INHIBITEURS DE XANTHINE CB1
Abstract
(EN)
Disclosed are compounds having structural formula (I), and related pharmaceutical compositions. Also disclosed are therapeutic methods, e.g., of treating diseases such as diabetic kidney disease, diabetic nephropathy, obesity-related kidney disease, focal segmental glomerular sclerosis, IgA nephropathy, nephrotic syndrome, kidney fibrosis, Prader Willi syndrome, metabolic syndrome, gastrointestinal diseases, non-alcoholic liver disease, alcoholic liver disease, or non-alcoholic fatty liver disease, using the compounds of Formula (I).
(FR)
L'invention concerne des composés ayant la formule de structure (I), et des compositions pharmaceutiques associées. L'invention concerne également des procédés thérapeutiques, par exemple, de traitement de maladies telles qu'une maladie rénale diabétique, la néphropathie diabétique, une maladie rénale liée à l'obésité, la sclérose glomérulaire segmentaire focale, l'hématurie idiopathique bénigne, le syndrome néphrotique, la fibrose rénale, le syndrome de Prader Willi, le syndrome métabolique, les maladies gastro-intestinales, la maladie hépatique non alcoolique, la maladie hépatique alcoolique ou la stéatose hépatique non alcoolique, à l'aide des composés de formule (I).
Latest bibliographic data on file with the International Bureau